Zimmer Biomet Holdings

US · ZBH #1040 by market cap Listed 1970

88.49 -1.19 -1.33%

Live - 5344 symbols - heartbeat 375s ago · 2026-10-07 20:02

After-hours 88.00 -0.55%

Market cap: 16.88B
P/E (TTM): 21.48
P/B: 1.34
EPS: 3.55
Div yield: 1.08%
52W pos: 36%

Reader sentiment Are you bullish or bearish on ZBH?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Fair

Altman Z-Score is 2.36, in the 1.8-3.0 "grey zone".
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +7.20% YoY

Margins

Gross margin: 69.71%
Operating margin: 16.48%
Net margin: 8.57%

Key ratios & quality

Enterprise value: 23.81B
PEG ratio: 0.48
Altman Z-Score: 2.36

PEG uses trailing P/E against the 3-year net income growth rate (44.98%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	7.93B	7.98B	6.13B	6.83B	6.94B	7.39B	7.68B	8.23B
Gross profit	5.66B	5.73B	4.30B	4.87B	4.92B	5.31B	5.49B	5.74B
Selling & admin expenses	3.38B	3.34B	2.71B	2.84B	2.76B	2.84B	2.93B	3.26B
Research & development	391.70M	449.30M	322.80M	435.80M	406.00M	458.70M	437.40M	458.50M
Operating profit	1.15B	1.27B	704.70M	1.01B	1.19B	1.45B	1.53B	1.36B
Pretax profit	-271.10M	905.80M	-105.20M	499.00M	403.50M	1.07B	1.04B	830.80M
Tax	108.20M	-225.70M	-96.00M	53.50M	112.30M	42.20M	131.40M	125.70M
Net profit	-379.30M	1.13B	-137.40M	402.10M	232.40M	1.03B	905.20M	705.10M
Basic EPS	-2	6	-1	2	1	5	4	4
Diluted EPS	-1.86	5.47	-0.67	1.91	1.10	4.88	4.43	3.55

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	1.91B	2.08B	2.00B	2.24B	2.09B	2.18B
Gross profit	1.36B	1.49B	1.44B	1.45B	1.51B	1.54B
Selling & admin expenses	758.80M	814.80M	811.40M	872.30M	849.90M	899.30M
Research & development	110.60M	113.30M	115.90M	118.70M	103.40M	104.80M
Operating profit	338.90M	396.40M	338.30M	282.60M	395.10M	374.00M
Pretax profit	229.00M	224.60M	279.20M	98.00M	301.30M	255.10M
Tax	46.50M	71.20M	48.00M	-39.90M	63.00M	55.50M
Net profit	182.60M	153.40M	231.20M	137.90M	238.30M	199.60M
Basic EPS	1	1	1	1	1	1
Diluted EPS	0.91	0.77	1.16	0.71	1.22	1.03

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	4.43B	4.72B	5.08B	4.89B	4.43B	4.61B	4.67B	5.12B
Cash & ST investments	542.80M	617.90M	802.10M	378.10M	375.70M	415.80M	525.50M	591.90M
Inventory	2.26B	2.39B	2.45B	2.15B	2.15B	2.39B	2.24B	2.29B
Total assets	24.13B	24.64B	24.42B	23.46B	21.07B	21.50B	21.37B	23.09B
Total current liabilities	2.42B	3.44B	2.56B	3.47B	2.36B	2.86B	2.45B	2.58B
Short-term debt	525.00M	1.50B	500.00M	1.61B	544.30M	900.00M	863.00M	587.10M
Long-term debt	8.41B	6.72B	7.63B	5.46B	5.15B	4.87B	5.34B	6.93B
Total liabilities	12,850,700,000.00	12,245,900,000.00	12,218,300,000.00	10,790,000,000.00	9,039,000,000.00	9,008,800,000.00	8,889,100,000.00	10,385,900,000.00
Total equity	11.28B	12.39B	12.20B	12.67B	12.03B	12.49B	12.48B	12.71B
Retained earnings	9.49B	10.43B	10.09B	10.29B	9.56B	10.38B	11.10B	11.61B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	5.59B	5.05B	5.83B	5.12B	4.96B	5.10B
Cash & ST investments	1.38B	556.90M	1.29B	591.90M	424.20M	410.00M
Inventory	2.24B	2.45B	2.48B	2.29B	2.25B	2.27B
Total assets	22.18B	22.87B	23.49B	23.09B	22.72B	22.80B
Total current liabilities	2.29B	2.70B	2.40B	2.58B	2.86B	3.01B
Short-term debt	600.00M	820.00M	600.00M	587.10M	1.18B	1.20B
Long-term debt	6.58B	6.75B	7.51B	6.93B	6.30B	6.28B
Total liabilities	9,780,100,000.00	10,330,800,000.00	10,722,000,000.00	10,385,900,000.00	10,040,000,000.00	10,165,300,000.00
Total equity	12.40B	12.53B	12.77B	12.71B	12.68B	12.63B
Retained earnings	11.23B	11.34B	11.52B	11.61B	11.80B	11.96B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	1.75B	1.59B	1.20B	1.50B	1.28B	1.58B	1.50B	1.70B
Depreciation & amortization	1.04B	1.01B	898.40M	937.70M	926.40M	951.70M	996.30M	1.09B
Free cash flow	1.58B	1.18B	1.09B	1.35B	1.07B	1.19B	1.14B	1.42B
Dividends paid	-195.20M	-196.70M	-198.50M	-200.10M	-201.20M	-200.90M	-196.00M	-190.30M
Stock buybacks / issuance	--	--	0	0	-126.40M	-692.20M	-868.00M	-487.00M
Ending cash balance	542.80M	617.90M	802.10M	478.50M	375.70M	415.80M	525.50M	591.90M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	382.80M	378.20M	418.70M	517.40M	359.40M	447.80M
Depreciation & amortization	254.40M	271.80M	283.60M	284.00M	270.00M	270.80M
Free cash flow	335.80M	298.10M	353.70M	432.60M	284.10M	331.40M
Dividends paid	-47.80M	-47.50M	-47.50M	-47.50M	-46.90M	-46.50M
Stock buybacks / issuance	-229.80M	-7.20M	0	-250.00M	-250.10M	-250.70M
Ending cash balance	1.38B	556.90M	1.29B	591.90M	424.20M	410.00M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	-3.30	9.57	-1.13	3.23	1.88	8.36	7.25	5.60
ROA %	-1.51	4.64	-0.57	1.68	1.04	4.81	4.22	3.17
ROIC %	-0.80	6.36	0.08	3.01	1.87	6.77	5.93	4.90
5-year avg ROE %	5.96	5.63	5.04	5.06	2.05	4.38	3.92	5.26
EBIT margin %	0.23	14.19	-0.89	8.00	8.19	17.16	16.34	13.65
FCF / sales %	19.98	14.80	15.47	16.83	15.80	16.28	14.88	17.25
Current ratio	1.83	1.37	1.99	1.41	1.88	1.61	1.91	1.98
Quick ratio	0.75	0.58	0.88	0.47	0.75	0.65	0.82	0.89
Debt / assets	37.05	33.37	33.28	30.14	27.04	26.83	29.04	32.56
LT debt / equity	74.65	54.26	62.54	43.15	42.86	39.00	42.84	54.59
Interest coverage	0.06	4.99	-0.29	3.01	3.45	6.30	5.76	3.84
Revenue CAGR (3Y) %	9.77	1.35	-7.74	-4.88	-4.56	6.46	3.99	5.85
Net income CAGR (3Y) %	--	54.66	--	--	-41.09	--	31.05	44.98
FCF CAGR (3Y) %	32.44	-6.56	-8.50	-5.27	-3.33	2.80	-5.34	10.00

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	7.31	6.52	6.41	5.60	6.07	6.42
ROA %	4.19	3.71	3.56	3.17	3.39	3.53
ROIC %	5.88	5.41	5.18	4.90	5.09	5.26
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	16.68	15.76	16.29	13.65	14.25	14.37
FCF / sales %	17.52	17.67	17.59	17.25	16.27	16.47
Current ratio	2.44	1.87	2.43	1.98	1.73	1.69
Quick ratio	1.27	0.80	1.20	0.89	0.75	0.72
Debt / assets	32.35	33.12	34.54	32.56	32.88	32.81
LT debt / equity	53.06	53.91	58.89	54.59	49.67	49.73
Interest coverage	5.50	4.72	4.61	3.84	4.06	4.23
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Diversified

Knees is the largest reported line at 38.08% of revenue, across 4 reported segments.
No single line clears half of revenue; Sports Medicine, Upper Extremities, Foot and Ankle; Trauma, Craniomaxillofacial and Thoracic (S.E.T) is next at 26.92%, spreading the business across more than one real driver.

Revenue breakdown most recent period

Business

Knees38.08%

Sports Medicine, Upper Extremities, Foot and Ankle; Trauma, Craniomaxillofacial and Thoracic (S.E.T)26.92%

Hips25.85%

Technology & Data, Bone Cement and Surgical9.16%

Quote time 2026-10-07 20:02:42 · For reference only, not investment advice and not tailored to your situation.